Previous 10 | Next 10 |
‒ Q3 2020 Net Revenue of $519 million; GAAP Net Loss of $(9) million; Diluted Loss per Share of $(0.06) ‒ ‒ Q3 2020 Adjusted Net Income (1) of $49 million; Adjusted EBITDA (1) of $114 million; Adjusted Diluted EPS (1) of $0.16‒ ...
Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is $0.12 (+200.0% Y/Y) and the consensus Revenue Estimate is $482.22M (+27.5% Y/Y).Over the last 2 years, AMRX has beaten EPS estimates 63% ...
[[AES]], [[AMRX]], [[COTY]], [[CQP]], [[CVS]], [[CWT]], [[DISH]], [[DOC]], [[ELAN]], [[ENB]], [[EPZM]], [[ESNT]], [[GCP]], [[GOLF]], [[HMSY]], [[HRC]], [[HSY]], [[LNG]], [[MAR]], [[MBUU]], [[MD]], [[MGA]], [[MOG.A]], [[MYL]], [[PRIM]], [[SABR]], [[SSP]], [[TILE]], [[TU]], [[UFS]], [[VIAC]], [...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2020 financial results on Friday, November 6, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern...
Amneal Pharmaceuticals, Inc. (NYSE:AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, work...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store brand equivalent Voltaren® Arthritis Pain Gel (diclofenac sodium topical gel, 1%) in 50, 100 and 1...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with this Read more ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conference held on September 15, 2020. The presentation will begin at 4:15 PM Eastern Time and a live webcast will be acc...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Lidocaine Patch, 5%. Lidocaine Patc...
WARSAW, Ind., Aug. 12, 2020 (GLOBE NEWSWIRE) -- WishBone Medical, Inc., a leader in pediatric orthopedic medical devices, is pleased to announce the appointment of Jeff George, global healthcare executive and investor, to the company’s board of directors, effective August 12, 2020. ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...